Literature DB >> 10912527

Role of parathyroid hormone-related peptide and Indian hedgehog in skeletal development.

H Jüppner1.   

Abstract

Parathyroid hormone-related peptide (PTHrP), which frequently causes the humoral hypercalcemia of malignancy syndrome, is an autocrine/paracrine regulator of chondrocyte proliferation and differentiation that acts through the PTH/PTHrP receptor (PTH1R). PTHrP is generated in response to Indian hedgehog (Ihh), which mediates its actions through the membrane receptor patched, but interacts also with hedgehog-interacting protein (Hip). Mice lacking PTHrP show accelerated chondrocyte differentiation, and thus premature ossification of those bones that are formed through an endochondral process, and similar but more-severe abnormalities are observed in PTH1R-ablated animals. The mirror image of these skeletal findings, i.e., a severe delay in chondrocyte differentiation and endochondral ossification, is observed in transgenic mice that overexpress PTHrP under the control of the alpha1(II) procollagen promoter. Severe abnormalities in chondrocyte proliferation and differentiation are also observed in two genetic disorders in humans that are most likely caused by mutations in the PTH1R. Heterozygous PTH1R mutations that lead to constitutively activity were identified in Jansen metaphyseal chondrodysplasia, and homozygous or compound heterozygous mutations that lead to less-active or completely inactive receptors were identified in patients with Blomstrand lethal chondrodysplasia. Based on the growth plate abnormalities observed in these human disorders and in mice with abnormal expression of either PTHrP or the PTH1R, it appears plausible that impaired expression of PTHrP and/or its receptor contributes to the growth abnormalities in children with end-stage renal disease. In fact, mild-to-moderate renal failure leads in animals to a reduction in PTH1R expression in growth plates and impaired growth, but it remains uncertain whether this contributes to altered chondrocyte growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912527     DOI: 10.1007/s004670000343

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  7 in total

1.  PTHrP 1-141 and 1-86 increase in vitro bone formation.

Authors:  Blake Eason Hildreth; Jillian L Werbeck; Nandu K Thudi; Xiyun Deng; Thomas J Rosol; Ramiro E Toribio
Journal:  J Surg Res       Date:  2010-03-16       Impact factor: 2.192

Review 2.  A bit of give and take: the relationship between the extracellular matrix and the developing chondrocyte.

Authors:  Danielle J Behonick; Zena Werb
Journal:  Mech Dev       Date:  2003-11       Impact factor: 1.882

Review 3.  Molecular basis for skeletal variation: insights from developmental genetic studies in mice.

Authors:  C Kappen; A Neubüser; R Balling; R Finnell
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2007-12

4.  Small RNAs derived from lncRNA RNase MRP have gene-silencing activity relevant to human cartilage-hair hypoplasia.

Authors:  Leslie E Rogler; Brian Kosmyna; David Moskowitz; Remon Bebawee; Joseph Rahimzadeh; Katrina Kutchko; Alain Laederach; Luigi D Notarangelo; Silvia Giliani; Eric Bouhassira; Paul Frenette; Jayanta Roy-Chowdhury; Charles E Rogler
Journal:  Hum Mol Genet       Date:  2013-09-05       Impact factor: 6.150

5.  Functional characterization and evolution of PTH/PTHrP receptors: insights from the chicken.

Authors:  Pedro L C Pinheiro; João C R Cardoso; Deborah M Power; Adelino V M Canário
Journal:  BMC Evol Biol       Date:  2012-07-06       Impact factor: 3.260

6.  Normal proliferation and differentiation of Hoxc-8 transgenic chondrocytes in vitro.

Authors:  Stephania A Cormier; Maria Alice Mello; Claudia Kappen
Journal:  BMC Dev Biol       Date:  2003-04-24       Impact factor: 1.978

Review 7.  Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved.

Authors:  Benjamin Ka Seng Thong; Soelaiman Ima-Nirwana; Kok-Yong Chin
Journal:  Int J Environ Res Public Health       Date:  2019-05-05       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.